Powered by Gastroenterology & Hepatology APP Experts

The Digital Learning Hub for Gastroenterology & Hepatology APPs

Welcome to the GHAPP Digital Hub. GHAPP is committed to developing educational programs, advancing APP professional development, and curating resources for — and guided by — advanced practice providers in GI & liver care.

Featured Resources

Faculty

Alison Moe

PA-C

Atlanta, GA, USA

Elizabeth Goacher

PA-C, MHS

Raleigh, NC

Ann Moore

NP

Phoenix, AZ

Christina Hanson

FNP-C

South Denver Gastroenterology

Gabriella McCarty

NP-C

North Shore Gastroenterology

Tedra Gray

NP-C

Sinai Medical Group

Kimberly Orleck

PA-C

Atlanta Gastroenterology Associates

Anne Feldman

NP

Cleveland Clinic Cleveland, OH

Corrie Berk

NP

The Texas Liver Institute

Lisa Richards

NP

UC San Diego

Jonathan Yeh

PA

Columbia University Irving Medical Center

Whitney Steinmetz

NP

Presbyterian Healthcare Services

Patrick Horne

NP

University of Florida

April Morris

FNP

Liver Institute of Virginia

Robin Soto

NP

UC San Diego Health

MASH

April 2026

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

April 2026

Podcast: Best Practices For MASH Patient Identification

March 2026

Mastering MASH Management: A 4-Pillar Approach to Patient Care in 2026

January 2026

FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?

January 2026

FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?

January 2026

Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment

January 2026

FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?

December 2025

Journal Club: Review of Focused Recommendations for the Management of MASLD by APPs in the US

December 2025

Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations

December 2025

FAQ: What Are the Functional and Prognostic Differences Between Fibrosis F3 and F4 Patients? How Are These Patients Managed Differently?

March 2025

Navigating New Horizons: Evolutions of MASH Care

February 2025

Post Conference MASH Highlights from AASLD

February 2025

Post Conference MASH Highlights From ACG

February 2025

Post Conference MASH Highlights From EASL

February 2025

Post Conference MASH Highlights From DDW

November 2024

Defining, Diagnosing, & Treating MASH

November 2025

Lifestyle Modifications for Patients With MASH

November 2025

Treatment of Metabolic Disorders and the Role of APPs in MASH

November 2025

Updates On Approved Treatments for MASH

November 2025

MASH Bootcamp Q&A

November 2025

Identifying & Diagnosing MASH Patients with Non-Invasive Tests

October 2024

What is Resmetirom and How Does It Work to Treat MASH?

October 2024

GHAPPcast: Recognizing the Severity of MASH

September 2024

What Is the Clinical Profile of Resmetirom, Including Dosing Schedules?

September 2024

How Is MASH Severity Staged? What Would an Ideal MASH NIT Algorithm Look Like?

September 2024

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

September 2024

What Are the Consequences of MASH Going Untreated?

September 2024

What is MASH?

IBD

May 2026

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

May 2026

Medication Review: Stable PK Supporting Continuous Inflammatory Control

April 2026

ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

April 2026

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

March 2026

SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC

March 2026

FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?

March 2026

Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data

February 2026

Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results

February 2026

Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know

February 2026

FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications

February 2026

FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?

November 2025

GHAPPcast: Women of Childbearing Age With IBD

November 2025

FAQ: How Do You Explain Remission To A Patient?

November 2025

GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient

October 2025

Targeting the Drivers of IBD: GHAPP National 2025

October 2025

FAQ: What Is the Importance of Biomarkers Such as Fecal Calprotectin and CRP?

October 2025

FAQ: What Are the Next Steps When a Patient Still Has Active Disease When Taking Advanced Therapy?

September 2025

APP Insight: Why Is It Important to Let Patients Know There Are Different Options for Treatment?

March 2025

The Clinical Utility of Guselkumab in CD

March 2025

Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3

March 2025

Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study

March 2025

GHAPPcast: The Clinical Utility of Guselkumab in UC

February 2025

Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results

February 2025

How Does the Guselkumab Data Align With the STRIDE II Guidelines?

February 2025

What Are Guselkumab's Other FDA Indications and How Might That Affect Patient Care?

February 2025

What Are Predictive Risk Factors for Disease Severity in CD and UC?

February 2025

Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results

February 2025

What Is the Efficacy of Guselkumab in Ulcerative Colitis and Crohn's Disease?

February 2025

What Is the Safety Profile of Guselkumab in Ulcerative Colitis and Crohn's Disease?

January 2025

Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study

January 2025

Is There a Correlation Between Myeloid Cells Expressing CD64 and Endoscopic Disease Severity?

January 2025

Why Is Binding CD64+ Important When Discussing IL-23 Directed Therapy?

January 2025

How Is Guselkumab Dosed in IBD?

January 2025

GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications

January 2025

Provide Immunologic Rationale for IL-23 Directed Therapy in IBD

January 2025

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

January 2025

What Is Non-Responder Imputation and How Is It Utilized in Clinical Trials?

December 2024

What Is the Role of the IL-23/IL-17 Axis in IBD?

December 2024

GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD

December 2024

Describe the IL-23/IL-17 Axis

December 2024

Describe the Mechanism of Action of Guselkumab

December 2024

Define, Compare, and Contrast Humoral and Cell-Mediated Immunity

October 2024

2024 IBD Bootcamp

IBS-C

November 2025

APP Insight: How Do You Develop a Treatment Plan for IBS-C? What Are Some Considerations?

October 2025

GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options

October 2025

APP Insight: Conducting Meaningful Conversations to Assess Therapy Impact

September 2025

GHAPPcast: Explaining IBS-C: Diagnosis and Communication That Builds Confidence

September 2025

APP Insight: Evaluating Time to Response and Treatment Effectiveness

July 2025

What Is the Difference Between CIC and IBS-C?

July 2025

GHAPPcast: Lifestyle and Nutrition Interventions for Constipation

July 2025

APP Insight: Discussing Exercise as a Complement to IBS-C Treatment

July 2025

GHAPPcast: Mental Health Issues and Symptoms Related to IBS-C

July 2025

FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?

July 2025

APP Insight: Provide Diagnostic Tips for IBS-C

July 2025

Using the Bristol Stool Scale to Measure Response to Treatment

July 2025

FAQ: What Are the Main Causes of IBS, and How Does the Disease Progress Over Time?

June 2025

Setting Expectations When Initiating New Therapy

June 2025

Diagnosing IBS With Confidence

June 2025

Diagnosing EPI and Managing With The Appropriate PERT Dosing

May 2025

Implementing the IBS Guideline

September 2024

GHAPPcast: Navigating IBS: Pathophysiology, Neuromodulators, and Patient-Centered Care

September 2024

What Resources Do You Use to Understand the Latest Approaches to Managing IBS-C Patients?

September 2024

Best Practices to Accelerate the Time to Finding the Right Therapy for Your Patients With IBS-C?

September 2024

Best Practices in Determining Clinically Meaningful “Response” to Therapy for IBS-C Patients?

September 2024

Mastering IBS-C: Diagnostic Strategies, Differentiation, and Management.

PBC

March 2026

PBC & PSC: Advancing Diagnostics, Novel Therapeutics and Patient Centered Management Symposium

January 2026

Expert Perspectives on Chronic Liver Disease From ACG & AASLD

September 2025

Empowering PBC Patients: APPs’ Role in Education and Support

August 2025

Navigating Difficult Conversations: Discussing Prognosis and Lifelong Care in PBC

August 2025

Collaborating Across Specialties: How APPs Can Work with Hepatologists & Other Providers in PBC Care

August 2025

Managing PBC Symptoms in the Real World: Practical Tips for APPs

May 2025

PBC Progression and Benefits of Early Diagnosis

May 2025

What is PBC?

May 2025

Epidemiology and Risk Factors of PBC

May 2025

PBC Case Presentation With Dr. Brown

March 2025

Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA

March 2025

Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively

March 2025

Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically

March 2025

Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression

March 2025

Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy

March 2025

Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy

March 2025

Building a Sense of Urgency for PBC Patient Evaluation/Monitoring

March 2025

Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis

October 2024

GHAPP PBC Podcast Series Part 2: New Therapeutics In The PBC Space

October 2024

GHAPP PBC Podcast Series Part 1: Prevalence, Awareness and Identification of PBC

October 2024

KOL Conversation: A New Treatment Option

IMID & Obesity

December 2025

The Conversation That Matters: Talking to Patients About Obesity and IMIDs

November 2025

From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs

November 2025

The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs

November 2025

Podcast: Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts

Cirrhosis

January 2026

Expert Perspectives on Chronic Liver Disease From ACG & AASLD

March 2025

What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?

February 2025

KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?

February 2025

What Should Patients Know About Living With Cirrhosis?

February 2025

What Lifestyle Changes Are Essential for Managing Cirrhosis Effectively?

February 2025

How Can You Support a Shared Decision Making Process With the Patient?

February 2025

How Can Physicians Better Care for Patients With Cirrhosis?

January 2025

GHAPPcast Part 3: Provider & Patient Support

January 2025

GHAPPcast Part 2: Diagnosis and Management

January 2025

GHAPPcast Part 1: Understanding Chronic Liver Disease and Cirrhosis

Payer

September 2025

GHAPPcast: Payer Tutorial

March 2025

Simplifying Access: Evolving Drug Distribution Channels

March 2025

Simplifying Access: Prior Authorization Part 2

March 2025

Simplifying Access: Prior Authorization Part 1

CSID

November 2024

GHAPPcast: CSID in Adults: Clinical Pearls & the Patient Journey

Hepatic Encephalopathy

January 2026

Expert Perspectives on Chronic Liver Disease From ACG & AASLD

September 2024

GHAPP/CLDF Podcast: Cirrhosis and Hepatic Encephalopathy

Biosimilars

September 2024

What Does It Mean for a Biosimilar to Be Interchangeable, and Why Is That Important?

September 2024

GHAPPcast: Biosimilars and the Patient Perspective

September 2024

What is the Difference Between Biosimilars and Generics?

September 2024

Biosimilars Unveiled: Empowering APPs for Better Patient Conversations

Biomarkers

February 2026

FAQ: Biomarkers: The Non-Invasive Future of HCC Detection

October 2025

GHAPPcast: Smarter Surveillance: The Rise of Algorithms like GALAD and Their Path to Practice

October 2025

GHAPPcast: Decoding Diagnostics: Why Biomarker Development Phases Are Your Clinical Ally

September 2025

Setting the Standard in Biomarker Validation: EDRN Example & Lessons from Liver Cancer

Hepatitis

November 2025

Florida Viral Hepatitis Network: Hepatitis Elimination Series

Wilson's Disease

April 2025

Expert Perspectives on the Unmet Needs in Patients with Wilson Disease

Publications

Translating multiomics prediction into clinical care in Crohn's disease: Moving beyond proof of concept

May 2026

DNA methylation biomarkers associated with early gastric cardia carcinogenesis

May 2026

Bile acid metabolism dysregulation following Helicobacter pylori eradication promotes plasmid-mediated antimicrobial resistance in the gut microbiome

May 2026

Exclusive enteral nutrition improves radiological outcomes in adults with perianal fistulizing Crohn's disease: A real-world retrospective cohort study

May 2026

Comments on "Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: A Systematic Review and meta-Analysis"

May 2026

One Chromatin, Many Structures: From Ensemble Contact Maps to Single-Cell 3D Organization

May 2026

The JAK Inhibitor Paradox: A Mechanistic Divide Between Adaptive and Innate Immunity

May 2026

CD4+ T cells promote fibrosis during metabolic dysfunction-associated steatohepatitis

May 2026

A case of carbapenamase production in <em>Shigella flexneri</em> isolated in Ireland, 2025

May 2026

Gastric Cancer Incidence After Helicobacter pylori Eradication and Lifestyle-Related Risk Factors: A Population-Based Cohort Study

May 2026

First Report of National Consensus Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Iran

May 2026

Elucidating the Pathogenic Role of Helicobacter pylori Infection in Hematologic Disorders: Mechanistic Insights and Future Perspectives

May 2026

Efficacy and Safety of Vonoprazan-Based Dual Therapies With Different Antibiotics Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Four-Arm, Randomized Controlled Trial

May 2026

High Eradication Rate of a Potassium-Competitive Acid Blocker-Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real-World Study

May 2026

A Bidirectional Association Between Helicobacter pylori Infection and Hyperlipidemia: Clinical Evidence and Mechanistic Insights

May 2026

sectionimg

dotimg

Download the app and start using it now

Download on the App Store

GET IT ON Google Play